Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 7Lymphoma, B-Cell, Marginal Zone 5Gastritis 5Lymphoma 4Dyspepsia 4Peptic Ulcer 3Neoplasms 2Stomach Ulcer 1Skin Neoplasms 1Pseudomyxoma Peritonei 1Precancerous Gastric Lesions 1Neutropenia 1Neoplasms, Plasma Cell 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Infections 1Hematologic Neoplasms 1Helicobacter Infections 1Head and Neck Neoplasms 1Glioblastoma 1Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer 1Fever 1Familial primary gastric lymphoma 1Cystectomy 1Chemotherapy Effect 1Brain Neoplasms 1Atrophy 1

Interventions

sipuleucel-T 2enzalutamide 2pamiparib 1gallium 68 PSMA-11 1fluzoparib 1Vancomycin 1Prednisone 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Amoxicillin × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡